https://scholars.lib.ntu.edu.tw/handle/123456789/514735
標題: | The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential | 作者: | Fruchart J.-C. Santos R.D. Aguilar-Salinas C. Aikawa M. Al Rasadi K. Amarenco P. Barter P.J. Ceska R. Corsini A. Despr?s J.-P. Duriez P. Eckel R.H. Ezhov M.V. Farnier M. Ginsberg H.N. Hermans M.P. Ishibashi S. Karpe F. Kodama T. Koenig W. Krempf M. Lim S. Lorenzatti A.J. McPherson R. Nu?ez-Cortes J.M. Nordestgaard B?.G. Ogawa H. Packard C.J. Plutzky J. Ponte-Negretti C.I. Pradhan A. Ray K.K. Reiner Z. Ridker P.M. Ruscica M. Sadikot S. Shimano H. Sritara P. Stock J.K. TA-CHEN SU Susekov A.V. Tartar A. Taskinen M.-R. Tenenbaum A. Tokg?zo?lu L.S. Tomlinson B. Tybj?rg-Hansen A. Valensi P. Vrabl?k M. Wahli W. Watts G.F. Yamashita S. Yokote K. Zambon A. Libby P. |
關鍵字: | Atherogenic dyslipidemia; Diabetes; Inflammation; Pemafibrate (K-877); PROMINENT; Remnant cholesterol; Residual cardiovascular risk; Selective peroxisome proliferator-activated receptor alpha modulator; SPPARMalpha; Triglycerides; Visceral obesity | 公開日期: | 2019 | 出版社: | BioMed Central Ltd. | 卷: | 18 | 期: | 1 | 起(迄)頁: | 71 | 來源出版物: | Cardiovascular Diabetology | 摘要: | In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk. ? 2019 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066822428&doi=10.1186%2fs12933-019-0864-7&partnerID=40&md5=86ea08c85ae32a4eaefffc68f64c90a1 https://scholars.lib.ntu.edu.tw/handle/123456789/514735 |
ISSN: | 1475-2840 | DOI: | 10.1186/s12933-019-0864-7 | SDG/關鍵字: | high density lipoprotein cholesterol; peroxisome proliferator activated receptor alpha agonist; triacylglycerol; (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid; antilipemic agent; benzoxazole derivative; biological marker; butyric acid derivative; lipid; peroxisome proliferator activated receptor alpha; PPARA protein, human; atherogenesis; cardiometabolic risk; cardiovascular risk; conceptual framework; coronary artery atherosclerosis; disease association; disease exacerbation; drug efficacy; drug safety; dyslipidemia; high risk patient; human; lipoprotein metabolism; non insulin dependent diabetes mellitus; nonalcoholic fatty liver; population research; preclinical study; prevalence; Review; risk factor; risk reduction; treatment outcome; treatment planning; triacylglycerol blood level; animal; blood; cardiovascular disease; consensus; dyslipidemia; metabolism; molecularly targeted therapy; patient safety; risk assessment; signal transduction; Animals; Benzoxazoles; Biomarkers; Butyrates; Cardiovascular Diseases; Consensus; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Molecular Targeted Therapy; Patient Safety; PPAR alpha; Risk Assessment; Risk Factors; Signal Transduction; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。